Abstract Hemophilia A (HA) and B are inherited bleeding disorders caused by a deficiency
of factor VIII or factor IX, respectively. The current standard of care is the administration of …

Introduction Emicizumab is a bispecific monoclonal antibody developed to address the
unmet needs of clotting factor replacement therapy and has become the benchmark for …

The next frontier in hemophilia A management has arrived. However, questions remain
regarding the broader applicability of new and emerging hemophilia A therapies, such as …

Background Emicizumab is a humanized bispecific monoclonal antibody that bridges
activated factor IX (FIXa) and factor X (FX) to mimic the function of factor VIII (FVIII). It …

Abstract Background Hemophilia A (HA) is a genetic bleeding disorder characterized by the
deficiency of the coagulation protein factor (F) VIII (FVIII). The development of neutralizing …

Introduction Hemophilia A is a genetically conditioned disease leading to hemostatic
disorders due to factor VIII (FVIII) deficiency. The treatment of hemophilia has evolved …

Abstract Background Acquired hemophilia A (AHA) is a rare and severe bleeding disorder
characterized by autoantibodies inhibiting coagulation factor VIII (FVIII). Current treatment of …

The first patient is a 32-year-old male, with no previous history of FVIII inhibitor who was
investigated owing to a spontaneous joint bleeding after his fourth emicizumab ED. We …

Background With the treatment landscape continually evolving, it is vital that the hemophilia
community have an overview of all published data for approved therapies, such as …

Emicizumab is a bi-specific antibody that in recent years has been introduced in many
countries as a prophylactic agent for bleed prevention in cases of severe hemophilia A, and …